zurich, switzerland, october 25, 2013 haselmeier has announced the ce mark ofjuniorstar® by sanofi. juniorstar® is a new easytouse, halfunit insulin reusable pen thatcan be used with lantus® insulin glargine, apidra® insulin glulisine or insuman®recombinant human insulin. developed and manufactured by haselmeier, juniorstar® is alight weight reusable pen with a large dose display, singlestep dial back without insulin leakageand delivers from 1 to 30 units per injection.&ldquohaselmeier is proud to partner with sanofi on this important program to develop andmanufacture juniorstar® and we look forward to continuing our business relationship in thefuture.&rdquo said frédéric gabriel, general manager of haselmeier.director project management at haselmeier, sandra de haan adds that &ldquothe excellentcooperation between sanofi and haselmeier project teams ensured announcement to thediabetes community at the recent easd congress.&rdquohalfunit dose increment pens provide flexibility to achieve target insulin doses especially inyoung patients with diabetes. juniorstar® has been tested by people with type 1 diabetes 6to 18 years old, parents and nurses in a noncomparative survey with 167 insulin pen usersfrom five european countries1· 81 of patientsparents and 86 of nurses agreed it is easy to carry on a daily basis,due of its light weight 34 grams· 98 of patientsparents and 94 of nurses agreed it is easy to read due to its largedose display and legible numbers· additionally, 91 of patientsparents and 89 of nurses agreed that the dialling backwas easy due to its singlestep dial back without insulin leakage· overall, 93 of survey participants agreed on its ease of use.juniorstar® meets the new iso 1160812012 standard and passed all requirements forrobustness and dose accuracy. it is offered in three different colors blue, red and silver, forflexibility and insulin differentiation.juniorstar® is expected to be available in europe and canada throughout 2014.references1. klonoff d et al., evaluation of the juniorstar® halfunit insulin pen in young people withtype 1 diabetes user perspectives. european endocrinology. 2013 92825.about sanofisanofi, a global and diversified healthcare leader, discovers, develops and distributestherapeutic solutions focused on patients&rsquo needs. sanofi has core strengths in the field ofhealthcare with seven growth platforms diabetes solutions, human vaccines, innovative drugs,consumer healthcare, emerging markets, animal health and the new genzyme. sanofi is listedin paris euronext san and in new york nyse sny.about haselmeierhaselmeier is a leading designer and manufacturer of pen and autoinjection systems. thecompany&rsquos devices feature unique function, design and technology and are marketed by leadingpharmaceutical and biotechnology companies around the world.for more information please visit www.haselmeier.comcontacthaselmeier gmbhdufourstrasse 328008 zürichswitzerlandnadia di seclitel 41 44 250 58 50n.secli@haselmeier.com